Published
2015-05-13

How to Cite

Almonacid, C. C., Cantillo Turbay, J., Quintana, J. C., Quiroga, L. A., & Parrado, Y. A. (2015). Ausencia de interferencias por anticuerpos heterófilos en la cuantificación de Troponina I Cardíaca, en pacientes con insuficiencia renal crónica terminal en tratamiento de hemodiálisis. NOVA Biomedical Sciences Journal, 1(1), 32-36. https://doi.org/10.22490/24629448.1048
Metrics
Metrics Loading ...

Ausencia de interferencias por anticuerpos heterófilos en la cuantificación de Troponina I Cardíaca, en pacientes con insuficiencia renal crónica terminal en tratamiento de hemodiálisis

DOI: https://doi.org/10.22490/24629448.1048
Section
Article (before OJS)
Carmen Cecilia Almonacid Universidad Colegio Mayor de Cundinamarca
Jorge Cantillo Turbay Servicio de Terapia Renal Hospital Universitario Clínica San Rafael. Bogotá, Colombia.
Janneth Carolina Quintana Universidad Colegio Mayor de Cundinamarca
Lorena Astrid Quiroga Universidad Colegio Mayor de Cundinamarca
Yolima Andrea Parrado Universidad Colegio Mayor de Cundinamarca
Absence of interferences for heterophilic antibodies in the quantification de cardiac Troponin I, in patients with terminal chronic renal inadequacy in hemodialysis treatment. The present study seeks to value the behavior of the addition of the blocking reagent of heterophilic antibodies (HBR), in the cardiac Troponin I quantification in patient with terminal chronicle renal inadequacy subjected to hemodialysis treatment. To each one of 70 patients with IRCt in hemodialysis treatment in the San Rafael University Hospital of Bogotá, they were taken a sample of serum and one of plasm heparanized in the pre dialysis, in which the TnIc concentrations were quantified with and without HBR addition, by means of the enzimoinmunoassay Axsym. The statistical test of Wilcoxon was used. The TnIc values in plasms and serums with and without the HBR addition didn't show significant differences (0.113 and 0.666 respectively), so much in the total of the patients as in those with chronic cardiac illness. Not having found differences in the TnIc values with and without HBR it takes us to think of the absence of heterophilic antibodies or in that the blocking reagent HBR doesn't have action in this population of patients.